News

search close

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

Read more

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022

Read more

Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events

Read more

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

Read more

Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Read more

Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

Read more

Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Read more

Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Read more

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

Read more

Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology

Read more